TuHURA Biosciences Inc (HURA)
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing cancer immunotherapy technologies. Its lead candidate, IFx2.0, is designed as an innate immune agonist intended to address primary resistance to checkpoint inhibitors, and the company is preparing to begin a Phase 3 registration study of IFx-2.0 as an adjunct treatment with Keytruda. TuHURA is also advancing its Delta receptor technology to create tumor microenvironment modulators, including bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting myeloid-derived suppressor cells. Additional development programs include Immune Fx and IFx-3.0, an mRNA innate immune agonist for intravenous or autologous whole-cell use in blood cancers. Founded in 1995 and based in Tampa, Florida, the company adopted the TuHURA Biosciences name in December 2023 and operates as a subsidiary of CohBar, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-HURA
|
$1.73
|
-22.2% Downside
|
Overvalued
|
$8.04
|
261.3% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-4.6x
|
6.2x
|
—
|
142.6 M
|
136.4 M
|
0.3%
|
62.3%
|
-2.8
|
0.0%
|
88.5%
|
